The biggest news in the markets today is SpaceX’s much‑anticipated IPO filing.

The company is aiming to raise roughly $75 billion at about a $1.75 trillion valuation, which would make it the largest IPO in history.

In its S‑1, filed May 20, 2026, SpaceX reports 2025 revenue in the high‑teens billions and a net loss of around $4.9 billion dollars, with a cumulative deficit in the tens of billions.

Interestingly, it seems that Rocket Man Elon’s biggest revenue generator wasn’t rockets at all … rather, the filing shows that connectivity (i.e. Starlink satellite internet) generated about $11.4 billion of revenue in 2025 and several billion dollars of operating income, while the launch and AI segments together still lost money.

In other words, the only clearly profitable pillar of Elon Musk’s space empire right now is a satellite internet business.

Starlink is printing cash for Musk, and that cash is helping fund rockets, deep‑space projects, and an aggressive AI build‑out.

Don’t think that Jeff Bezos missed the memo. Amazon is pouring billions into its 3,200‑plus‑satellite Project Kuiper constellation, turning low‑Earth‑orbit broadband into a full‑blown corporate space race.

So while most eyes this morning are glued to that $1.75 trillion figure with visions of massive rockets flying through the air …

… The real story might just be the impact that small low earth orbit (LEO) satellites are poised to make on a “space economy” that McKinsey estimates at $1.8 trillion.

And the good news is you don’t have to wait until SpaceX finally goes public to gain exposure to this market.

Just down the road from SpaceX and NASA at Cape Canaveral, there is a much smaller company positioning itself for the same satellite economy that Starlink just validated to the tune of multiple billions of dollars.

Starfighters Space (NASDAQ: FJET) is headquartered at Kennedy Space Center in Florida, operating out of a reusable launch vehicle hangar on Hangar Road in Cape Canaveral.

The company runs what it describes as the world’s only commercial fleet of flight‑ready F‑104 Starfighter supersonic aircraft, capable of sustained Mach 2 flight.

Starfighters Space (NASDAQ: FJET)  currently operates seven modified F‑104s that can be configured as first‑stage lifting platforms.

These jets are designed to carry small rockets and payloads to about 45,000 feet for air‑launch to space.

The goal is to enable sub‑orbital launches to around 100 kilometers with a system called STARLAUNCH 1, and then to reach low Earth orbit (160 kilometers and above) with a next‑generation system called STARLAUNCH 2, which is expected to offer roughly 49 percent more thrust.

In late 2025 and early 2026, the company announced milestones for its STARLAUNCH I program, including completion of preliminary designs, manufacture of test articles with GE Aerospace’s Innoveering unit, and plans for wind‑tunnel work and drop tests.

Starfighters Space (NASDAQ: FJET)  is also already generating revenue from adjacent activities. It offers pilot and astronaut training, in‑flight testing, and other aeronautics services to defense, civil, academic, and commercial customers.

Its F‑104 fleet supports hypersonic and high‑altitude test programs, and the company says that it is “market‑ready with minimal R&D effort” for its core flight operations while STARLAUNCH matures.

And this little-known company sits directly in the path of the trend SpaceX filing is igniting.

As more low‑Earth‑orbit constellations are funded—whether it is Starlink, Amazon’s 3,200‑plus‑satellite Amazon Leo project, or other regional and specialized networks — every one of those satellites needs a ride to orbit.

Large rockets will handle a lot of bulk deployment, but there is also demand for more targeted launches: smaller payloads, specific orbits, and more flexible timing.

This is the niche Starfighters Space (NASDAQ: FJET)  is aiming at.

And, with the SpaceX IPO filed, the fuse is officially lit for this niche to explode.

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of Starfighters Space, Inc. (NYSE: FJET). This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Starfighters Space, Inc. (NYSE: FJET) is the sole source of funds for a budget of approximately $725,000 provided to CDMG INC the advertising agency to cover the costs associated with creating, printing and distribution of this advertisement. The advertising agency will retain any excess sums after all expenses are paid. Readers should beware that the advertising agency and/or its owners ,officers, principals, or affiliates own shares and/or stock options of Starfighters Space, Inc. (NYSE: FJET) and therefore have an additional incentive to see the company’s stock perform well. This share ownership should be viewed as a major conflict with our ability to be unbiased. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, the advertising agency and their respective officers, principals, or affiliates will not sell securities of Starfighters Space, Inc. (NYSE: FJET). If successful, this advertisement will increase investor and market awareness of Starfighters Space, Inc. (NYSE: FJET) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement and the advertising agency do not purport to provide a complete analysis of Starfighters Space, Inc. (NYSE: FJET) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about Starfighters Space, Inc. (NYSE: FJET). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in Starfighters Space, Inc. (NYSE: FJET) SEC filings. Investing in microcap securities such as Starfighters Space, Inc. (NYSE: FJET) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agency cannot guarantee the accuracy or completeness of the information and is not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of Starfighters Space, Inc. (NYSE: FJET) and/or its industry. The advertising agency notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect Starfighters Space, Inc. (NYSE: FJET) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market Starfighters Space, Inc. (NYSE: FJET) products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agency is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.

For years, investors chased the giant pharmaceutical companies…

They bought the household names with massive balance sheets, billion-dollar drug portfolios, and global sales teams. 

But lately, some of the biggest gains in healthcare haven’t come from the giants themselves…

Instead, they’ve come from the tiny biotech firms getting swallowed whole.

And that’s because Big Pharma has a problem. Actually, several problems…

Patent cliffs are approaching. Competition is intensifying. Drug pipelines are aging. 

And developing entirely new therapy platforms internally is expensive, risky, and painfully slow.

So instead of building the next breakthrough from scratch, pharmaceutical giants are increasingly buying innovation outright.

And they’re paying enormous premiums to do it…

Over the past two years, we’ve seen an explosion of biotech acquisitions involving small companies with promising clinical-stage therapies, proprietary delivery systems, and next-generation treatment platforms. 

In many cases, these targets weren’t profitable. Some barely had revenue at all.

But they had something Big Pharma desperately wanted: potential.

That’s why investors willing to identify promising therapy platforms before the acquisition rumors start circulating could find themselves sitting on explosive upside.

And history suggests this trend is only accelerating…

Big Pharma Is Spending Billions to Refill Drug Pipelines

The merger-and-acquisition market across biotech has exploded as major pharmaceutical companies race to secure future growth. 

And analysts believe 2026 could become one of the biggest years for biotech dealmaking in recent memory as drugmakers confront looming patent expirations and slowing organic growth.

Just look at some of the recent deals…

Earlier this year, Johnson & Johnson agreed to acquire Intra-Cellular Therapies for roughly $14.6 billion. 

The attraction wasn’t just one drug. It was the company’s broader neuroscience platform and pipeline focused on mental health and neurological disorders.

Pfizer reportedly spent around $10 billion acquiring Metsera as competition in the obesity-treatment market intensified.

Meanwhile, Johnson & Johnson also agreed to buy Halda Therapeutics for more than $3 billion because of its RIPTAC cancer treatment platform, despite the company still being in the clinical development stage.

Bayer recently agreed to acquire Perfuse Therapeutics for up to $2.45 billion in a deal centered around an experimental therapy platform targeting glaucoma and diabetic retinopathy.

And Angelini Pharma just announced a $4.1 billion acquisition of Catalyst Pharmaceuticals to expand its rare disease and neurology footprint in the U.S. market.

Notice the pattern?

These aren’t mature companies getting bought because of stable cash flow. They’re emerging innovators with specialized therapy platforms and promising trial data.

That’s where the real value is migrating.

Why Small Biotech Platforms Have Become So Valuable

Modern drug development has changed dramatically…

Big Pharma no longer just wants a single blockbuster drug. It wants platforms that can produce multiple therapies across multiple diseases.

That’s why terms like CAR-T, antibody-drug conjugates, NK-cell therapies, gene editing, RNA therapies, and precision oncology have become so important.

One successful platform can generate an entire pipeline of future treatments.

And once clinical data begins showing promise, acquisition interest can arrive quickly.

This is especially true in oncology, autoimmune disease, neurology, and obesity treatments, where the market opportunities are measured in tens or even hundreds of billions of dollars annually.

The problem for retail investors is that by the time acquisition headlines hit the newswires, the easy money is usually already gone.

And that’s why the biggest gains often happen beforehand, when these companies are still flying under Wall Street’s radar.

Which is why keeping an eye on small clinical-stage biotech firms with differentiated technology platforms could become one of the most important speculative investment themes of the next few years.

Three Small Biotech Companies That Could Draw Acquisition Interest

One company that stands out in this environment is GT Biopharma (NASDAQ: GTBP).

GT Biopharma is developing an immuno-oncology platform focused on NK-cell engager therapies designed to target and destroy cancer cells. 

Unlike traditional T-cell therapies, NK-cell approaches could potentially offer safer treatment profiles, faster manufacturing, and broader applications across multiple cancer types.

The company’s TriKE platform has generated growing interest because it attempts to activate natural killer cells while simultaneously directing them toward cancer targets. 

That combination could eventually make therapies more effective while reducing some of the toxicity issues associated with older immunotherapy approaches.

Clinical-stage immunotherapy platforms have become one of the hottest acquisition categories in biotech because large pharmaceutical companies are aggressively competing to dominate the next generation of cancer treatment.

If GT Biopharma (NASDAQ: GTBP) can continue advancing clinical data and demonstrating platform versatility, it wouldn’t be surprising to see larger players begin paying muchncloser attention.

Another speculative name worth watching is Candel Therapeutics (NASDAQ: CADL)…

The company is developing viral immunotherapies designed to stimulate the immune system directly within tumors. 

Its platform combines viral vectors with immune activation strategies that could potentially enhance anti-tumor responses across several difficult-to-treat cancers.

What makes companies like this attractive acquisition candidates is scalability… 

If a platform demonstrates success in one indication, larger pharmaceutical companies immediately begin evaluating how broadly it can be expanded into additional cancer markets.

Then there’s Cargo Therapeutics (NASDAQ: CRGX), which is focused on next-generation CAR-T therapies designed to overcome resistance and relapse issues seen in existing blood cancer treatments.

CAR-T remains one of the most promising areas in oncology, but current therapies still face limitations tied to durability, manufacturing complexity, and patient relapse rates. 

Companies developing improved delivery mechanisms or enhanced targeting systems are attracting increasing attention across the industry.

That’s exactly the type of innovation larger pharmaceutical firms have been buying aggressively.

And remember, these acquisitions don’t always happen after Phase 3 trials or FDA approvals anymore…

Sometimes all it takes is compelling early-stage data and a platform that appears scalable.

The Window Before Wall Street Notices

Biotech investing is risky. There’s no way around that.

Clinical trials fail. Funding dries up. Regulators delay approvals. Promising therapies sometimes never make it to market.

But the rewards can also be enormous because success in biotech doesn’t always require full commercialization.

Sometimes success simply means attracting the attention of a bigger company with billions of dollars to spend and an urgent need to refill its pipeline.

That’s the environment we’re entering now.

Large pharmaceutical companies are sitting on mountains of cash while staring down patent expirations and slowing growth. 

At the same time, smaller biotech firms are developing revolutionary treatment platforms that could reshape entire areas of medicine.

That combination creates fertile ground for acquisition waves.

And investors who position themselves early could benefit long before the rest of Wall Street catches on.

That’s why now may be the time to start learning more about GT Biopharma (NASDAQ: GTBP), Candel Therapeutics (NASDAQ: CADL), and Cargo Therapeutics (NASDAQ: CRGX) before Big Pharma starts sniffing around and driving prices higher.

Because once acquisition rumors begin circulating, the market usually moves fast. And by then, a large chunk of the upside may already be gone.

Cancer is still the diagnosis nobody wants to hear.

It’s scary. It’s complicated. It’s personal. And it touches almost every family in some way.

But the story of cancer care has changed dramatically over the past several decades.

We’re no longer living in an age when doctors had just three blunt tools…

Cut it out, blast it with radiation, or poison it with chemotherapy and hope the cancer dies before the patient does.

Those tools still matter. Surgery, radiation, and chemotherapy remain major parts of cancer treatment. But they’re no longer the whole story.

Cancer Treatment Has Changed

Today, doctors can profile tumors by mutation. They can match patients with drugs designed for specific genetic drivers. They can use the immune system as a weapon. 

And they can deliver toxic payloads directly to cancer cells while sparing more healthy tissue. That’s a massive leap forward.

Thanks to those advances, the U.S. cancer death rate fell 34% from its 1991 peak through 2022, helping avert roughly 4.5 million deaths. 

That’s not a small improvement. It’s a revolution in slow motion.

We haven’t cured cancer. Not even close. But we’ve absolutely changed the odds.

The Market Is Following the Medicine

Now, here’s where the investment story begins…

Cancer isn’t just one disease. It’s hundreds of diseases hiding under the same ugly name.

Lung cancer isn’t breast cancer. Pancreatic cancer isn’t lymphoma. Melanoma isn’t ovarian cancer. 

And even within those categories, two patients with the “same” cancer can have very different molecular drivers.

That’s what makes oncology so hard. But it’s also what makes the market so enormous.

Every new insight creates a new target. Every new target creates a new drug candidate. Every new drug candidate creates a new clinical trial. 

And every successful clinical trial can create a new standard of care, a new revenue stream, and sometimes a multi-billion-dollar acquisition.

That’s why oncology remains one of the most valuable areas in all of health care.

Global spending on cancer medicines has already climbed into the hundreds of billions of dollars annually.

And analysts expect that number to keep rising as populations age, screening improves, treatment options expand, and more patients gain access to advanced therapies.

This isn’t growth for growth’s sake, though. There’s real demand behind it.

The American Cancer Society projects roughly 2.1 million new cancer cases and more than 626,000 cancer deaths in the United States in 2026. 

That’s about 5,800 new diagnoses every single day.

So yes, cancer care is a massive market. But it’s also a market driven by one of the most urgent needs in medicine. And that’s a powerful combination.

The Science Has Entered a New Phase

The old model of cancer treatment was largely based on location.

Where’s the tumor? Breast. Lung. Colon. Prostate. Blood. Brain.

While that still matters, increasingly, the more important question is: What’s driving the cancer?

Is there a mutation? A receptor? A protein? A pathway? A weakness the drug can exploit?

That shift has opened the door to targeted therapies, immunotherapies, antibody-drug conjugates, cell therapies, bispecific antibodies, radiopharmaceuticals, and other approaches that are reshaping cancer care.

Some of these treatments help the immune system recognize and attack cancer. Some act like guided missiles. Some block the signals cancer cells use to grow. 

Some bring immune cells and cancer cells into close contact so the body can do what it was designed to do.

It’s not clean. It’s not easy. And lot of experimental drugs fail. Some even fail after years of work and hundreds of millions of dollars are spent developing them.

That’s biotech.

But when it works, it can change lives. And when it changes lives, Wall Street notices.

Big Pharma Is Buying the Future

To see where Big Pharma thinks medicine is headed, don’t just listen to conference calls… You watch the checkbooks.

And if you’ve been watching then’ you’ve noticed that over the past few years, some of the biggest names in pharmaceuticals have spent enormous sums buying cancer platforms, cancer pipelines, and cancer drugs that started inside smaller, more focused companies.

Pfizer’s roughly $43 billion acquisition of Seagen is one of the clearest examples. 

That deal gave Pfizer a major position in antibody-drug conjugates, a class of cancer drugs designed to deliver cancer-killing agents more directly to tumor cells.

AbbVie made a similar move when it agreed to buy ImmunoGen for about $10.1 billion, strengthening its solid tumor pipeline and adding a targeted ovarian cancer therapy.

Bristol Myers Squibb also stepped deeper into oncology with its acquisition of Mirati Therapeutics, a deal valued at up to $5.8 billion including a contingent value right. 

That transaction added a targeted lung cancer drug and a broader cancer pipeline.

And those are just a few examples. But the bigger point is simple: Big Pharma needs innovation. And small biotech often creates it.

And when a little-known company develops something that could fill a pipeline gap, expand a cancer franchise, or threaten the current standard of care, the price tag can get very large very quickly.

The Patent Cliff Makes This More Urgent

There’s another force driving this trend: the patent cliff.

You see, big pharmaceutical companies live and die by exclusivity. A blockbuster drug can generate billions of dollars a year while it’s protected. 

But once generic or biosimilar competition arrives, sales can fall hard. And that creates a constant problem…

Big Pharma has to replace aging revenue streams before they roll over. And it’s often faster to buy innovation than to build it from scratch.

That’s why cancer-focused biotech companies can become so valuable even before they have major sales…

A promising platform, a strong mid-stage trial, or a treatment that works in a hard-to-treat cancer can turn a tiny company into a strategic asset.

The acquiring company isn’t just buying today’s revenue.

It’s buying tomorrow’s pipeline. It’s buying scientific talent. It’s buying intellectual property.

It’s buying a shot at the next standard of care. And in oncology, that shot can be worth billions.

This Is Where Speculation Lives

Now, let’s be honest. This isn’t like buying a railroad, a utility, or a dividend-paying toothpaste company.

Small biotech stocks are risky. Some are wildly risky. 

A single clinical trial result can make or break the whole story. A safety issue can wipe out years of progress. A financing problem can punish shareholders. A promising mechanism can look brilliant in early testing and disappoint in larger trials.

That’s why investors should never confuse excitement with certainty.

But speculation isn’t the same thing as gambling when there’s a real thesis behind it.

And in oncology, the thesis is pretty clear…

Cancer remains one of the world’s biggest medical problems. The market is enormous. The science is advancing. Big Pharma is hungry for pipeline assets. 

And the most explosive upside often starts in small companies most investors have never heard of.

That doesn’t mean every small cancer biotech is a winner. Many won’t be.

But the few that succeed can deliver life-changing advances for patients and portfolio-changing returns for early investors.

That’s what makes this corner of the market so fascinating…

It sits at the intersection of science, medicine, human need, and financial ambition.

Keep This Market in Focus

Cancer care has come a long way.

The death rate has fallen. Survival has improved. Treatments have become smarter. Patients have more options. Doctors have better tools. And researchers are still pushing.

That progress is the human story. And the investment story is what happens next.

Oncology is one of the few markets where scientific breakthroughs can create enormous social value and enormous financial value at the same time. 

That doesn’t make it safe. It doesn’t make it simple. And it sure doesn’t make every tiny biotech stock a future winner.

But it does make the cancer treatment market one of the most important places for investors to watch.

Because somewhere out there, a small company is working on a therapy that could change the way we treat cancer.

Maybe it fails. Maybe it gets bought. Maybe it becomes the foundation of the next great cancer franchise. That’s the opportunity.

So keep this market in focus. Keep watching the science. Keep watching the deal flow. 

And keep learning more about the small companies with big aspirations — and even bigger potential future profits.

Bankruptcy has a bad reputation and that makes sense. Nobody throws a party when a company collapses. 

Workers lose jobs. Investors get wiped out. Creditors start sharpening their knives. And lawyers show up by the truckload.

It’s not pretty.

But here’s the part most investors miss: Bankruptcy doesn’t always destroy value.

Sometimes, it reveals it…

That’s because a bankrupt company is often two very different things trapped inside the same ugly sweater.

On one side, you have the busted business. Too much debt. Bad management. Bloated costs. Poor timing. Maybe all of the above.

But on the other side, you often still have valuable assets…

Brands. Factories. Patents. Land. Customer relationships. Distribution networks. Intellectual property. Technology. Designs. Permits. Contracts.

The company may be dead, but the assets may be very much alive.

And throughout history, some of the smartest investors and operators have made fortunes by understanding that difference.

They didn’t buy the corpse… They bought the organs.

And then they built a new body around them.

The Twinkie That Came Back from the Dead

Hostess may be the most fitting (and delicious) example of this entire idea…

By 2012, the maker of Twinkies, Ding Dongs, Ho Hos, and other sugar-powered lunchbox legends was in bankruptcy. 

The company had iconic brands, but it was trapped under debt, legacy costs, labor fights, and an operating model that no longer worked.

To the casual observer, Hostess looked like a dead company.

But to Apollo Global Management and C. Dean Metropoulos, it looked like a fire sale on American nostalgia.

So, they stepped in…

They bought key Hostess snack-cake brands and bakeries. And that deal included Twinkies and other legendary Hostess products. 

But more importantly, it allowed the new owners to acquire the good assets without dragging along all the liabilities that helped sink the old company.

That’s the magic of many bankruptcy sales…

The buyer gets the good stuff. And the financial wreckage gets left behind.

Apollo and Metropoulos relaunched Hostess with a leaner cost structure, a modernized distribution model, and a renewed focus on the brands people still loved.

The Twinkie didn’t need to be invented. It just needed to be rescued.

And a decade later, J.M. Smucker agreed to acquire Hostess in a deal valued at roughly $5.6 billion.

That’s the bankruptcy treasure hunt in one snack-sized package…

A beloved brand fell into the ditch. Smart money pulled it out. Then Wall Street paid up.

Rust Belt Steel Became Wall Street Gold

Now let’s move from snack cakes to steel mills. Less delicious, but just as profitable…

In the early 2000s, American steel was about as popular as a root canal. 

Mills were going bankrupt. Pension obligations were massive. Foreign competition was brutal. Investors wanted software, not blast furnaces.

But Wilbur Ross saw something others didn’t. He saw that the steel assets themselves still had value.

The problem wasn’t necessarily the furnaces, mills, land, or industrial know-how. The problem was the old capital structure and legacy burden sitting on top of them.

So, Ross started buying bankrupt steel assets.

And he helped build International Steel Group by cobbling together mills from bankrupt companies, including pieces of LTV, Bethlehem Steel, and other distressed operators.

These were not glamorous assets. They were dirty, capital-intensive, and wildly out of favor.

Perfect… Because when nobody wants an asset, the price can get stupidly cheap.

Then the cycle turned and global steel demand improved. 

China was hungry for raw materials. Pricing recovered. The hated assets suddenly looked strategic again.

And in 2004, Mittal agreed to buy International Steel Group in a deal valued at about $4.5 billion.

That’s the second lesson…

Sometimes the best distressed deals aren’t about brands. They’re about capacity.

Factories. Mills. Infrastructure. Permits. Industrial assets that are difficult, expensive, and sometimes impossible to replace.

When the market hates them, they trade like scrap. But when the world needs them again, they trade like treasure.

Marvel Was an IP Vault In Disguise

Then there’s another household name that rivels Hostess: Marvel.

Today, Marvel is one of the most powerful entertainment brands on Earth. 

Iron Man, Captain America, Spider-Man, Black Panther, Thor, the Avengers — it’s hard to imagine modern pop culture without them.

But in the 1990s, Marvel was a mess…

The comic book bubble burst. Sales collapsed. The company filed for bankruptcy in 1996. 

And to many investors, Marvel looked like a fading comic book publisher tied to a shrinking market.

But that was the surface-level story. The deeper story was that Marvel owned a vault of characters with massive unrealized value.

The world didn’t need more comic books. It needed better ways to monetize stories.

Movies. Licensing. Toys. Video games. Television. Streaming. Merchandise. Theme parks. Global franchises.

Marvel eventually figured that out. And it stopped acting like a dying comic book company and started acting like an intellectual property machine.

By 2009, Disney bought Marvel for roughly $4 billion, completing one of the greatest entertainment turnarounds of the modern era.

And that’s the third lesson…

The most valuable asset in a distressed company may not look like an asset at all.

It may be a character, a patent, a design, a customer list, a license, a technical team, or a brand people forgot they still loved.

Marvel wasn’t saved because people suddenly became obsessed with bankruptcy proceedings.

It was saved because the underlying IP was worth far more than the market believed when the business was broken.

Pabst Proved Dead Brands Can Still Live

Pabst Blue Ribbon gives us another version of the same story…

PBR wasn’t a clean bankruptcy example like Hostess, but it fits the broader distressed-brand playbook beautifully.

It was old. It was tired. It certainly wasn’t winning the craft beer arms race. And it wasn’t exactly the future.

But then C. Dean Metropoulos bought Pabst in 2010 for about $250 million.

And a few years later, he sold it for around $700 million.

The genius wasn’t creating beer from scratch. The genius was recognizing that a forgotten brand still had cultural value.

PBR had history. Distribution. Recognition. A weirdly durable place in American drinking culture. It just needed the right owner and the right moment.

And that’s another key part of this strategy…

Distressed assets don’t always need a miracle. Sometimes they just need a better steward.

The Transfer of Value

All four stories point to the same big idea…

Bankruptcy and distress can create a transfer of value from weak hands to strong hands.

Hostess had beloved brands trapped inside a broken operating structure.

International Steel had hard industrial assets trapped inside a hated sector.

Marvel had priceless intellectual property trapped inside a collapsing comic book business.

Pabst had cultural brand equity trapped inside a tired beer company.

The buyers didn’t pay full price for perfection. They paid distressed prices for assets with a second life.

And that’s why this theme matters so much to investors today…

Because we’re entering an era where some of the most valuable assets in the world may not be snack cakes, steel mills, comic book heroes, or beer labels.

They may be nuclear reactor designs.

The Next Great Asset Transfer May Be Nuclear

Advanced nuclear energy is moving from science project to national priority in a hurry…

AI data centers need enormous amounts of reliable power. Industrial reshoring needs dependable baseload electricity. 

Remote mines, military bases, factories, islands, and off-grid communities need power that doesn’t depend on fragile fuel deliveries or overloaded transmission lines.

That’s why small modular reactors and micro modular reactors have moved from the fringe to the center of the energy conversation.

This isn’t the old nuclear story…

It’s not just about giant concrete domes that take decades, billions of dollars, and a small army of regulators to build.

This is about compact nuclear systems… Factory-built nuclear systems… Transportable nuclear systems…

Reactors that could one day power places the traditional grid can’t reach, won’t reach, or can’t serve reliably enough.

And right now, this emerging market may also be setting up one of the most fascinating distressed-asset stories in energy history.

Because one of the early pioneers in the space, Moltex Energy, has fallen into trouble…

Moltex Had the Kind of Technology the World May Soon Need

Moltex was not some random science project cooked up in a garage.

It was developing the Stable Salt Reactor-Wasteburner, or SSR-W, an advanced reactor concept designed to generate power using recycled nuclear waste.

That alone is a massive idea…

Nuclear power has always had two great public-relations problems: safety and waste. And Moltex was trying to attack both at once. 

Its reactor design was built around molten salt technology, and its broader pitch was simple but powerful: take used nuclear fuel, recycle it, and use it to generate clean, reliable baseload power.

In other words, take one of nuclear power’s biggest problems and turn it into fuel.

That’s not incremental. That’s potentially revolutionary.

Moltex had also developed WATSS, a technology intended to recycle used nuclear fuel. 

The company had reported progress in extracting transuranic material from used nuclear fuel, pushing forward the dream of turning yesterday’s nuclear waste into tomorrow’s clean power.

Again, that matters because the next energy boom won’t just be about building more power plants…

It’ll be about building better energy systems. Systems that are cleaner, more secure, more reliable, less dependent on foreign supply chains…

And capable of feeding the industrial, digital, and defense demands of the next decade.

Moltex seemed to have a real place in that story.

It had attracted government support. It had gained attention in Canada’s advanced nuclear push. 

It had been connected to plans in New Brunswick, where advanced reactor designs were being considered for future deployment.

This was not a dead idea. This was a valuable idea trapped inside a company that hit the wall.

A Broken Company Doesn’t Mean Broken Assets

This is where the distressed-asset angle becomes so important…

Moltex’s parent company entered administration, the British version of a bankruptcy-style insolvency process. 

The business and assets were put into a process where buyers could potentially step in.

And that creates the same kind of setup we saw in Hostess, International Steel, Marvel, and Pabst…

A company gets mismanaged. A company runs out of money. A company gets tangled in financial problems…

But the underlying assets may still have enormous value.

The designs still matter. The patents still matter. The technical work still matters.

The regulatory progress still matters. The team’s knowledge still matters.

The partnerships still matter. The market opportunity still matters.

And that’s the whole point…

The bankruptcy filing is not always the end of the story. Sometimes it is the beginning of the opportunity.

Especially when the asset sitting inside the wreckage is tied to a market as important as advanced nuclear energy.

The Smart Money Watches the Wreckage

The average investor sees bankruptcy and looks away but the smart investor always looks closer.

That doesn’t mean every distressed company is an opportunity. Most aren’t. 

Plenty of assets really are impaired. Plenty of businesses deserve to disappear. Plenty of turnarounds fail.

But every once in a while, distress creates a rare opening…

A valuable brand becomes available.

A steel mill changes hands at the bottom of the cycle.

A superhero library gets rescued from a broken comic book publisher.

A forgotten beer brand gets revived.

Or an advanced nuclear reactor design escapes a mismanaged company and lands in stronger hands.

That’s the story to watch now…

Moltex Energy’s distress process could become one of the most important value transfers in the nuclear market.

The company that wins the bid may gain access to advanced reactor designs, fuel-recycling technology, specialized expertise, and years of development work at a fraction of what it would cost to build from scratch.

And if that company can turn those assets into a real commercial platform, it could become the next multi-billion-dollar nuclear market unicorn.

So keep a close eye on the Moltex process… Watch for the winning bidder. Watch for the structure of the deal.

Watch for signs that valuable nuclear technology is moving from weak hands into stronger ones.

Because in business, value does not always disappear when a company falls apart…

Sometimes it simply changes owners.

And when that value involves advanced nuclear energy — one of the most important markets of the next decade — that transfer could be explosive.

The global energy map is being redrawn in real time.

The United Arab Emirates announced it will leave OPEC and OPEC+ effective May 1, delivering a major blow to the cartel’s ability to coordinate global oil production and pricing.

The UAE — one of the group’s largest producers — said it wants more flexibility to accelerate production and pursue its own long-term energy strategy.

This may be the clearest sign yet that President Donald Trump’s “global energy reset” is accelerating under the pressure of war, sanctions, and shifting trade routes.

For decades, OPEC and the Strait of Hormuz gave the Middle East enormous leverage over the global economy. Roughly a fifth of the world’s oil supply traditionally moved through that narrow waterway.

But the ongoing Iran conflict and repeated disruptions in Hormuz have exposed how fragile that system really is.

Trump’s response has been aggressive and transactional.

His administration has reportedly explored selective sanctions relief on Russian oil to stabilize global supply while simultaneously pressuring Iran and reshaping Venezuelan oil flows.

The strategy appears straightforward: weaken hostile chokepoints, increase non-OPEC production, and pull more global energy dependence toward American-aligned supply chains …

… All actions that seem to be pointed squarely at China.

China remains heavily dependent on imported oil from Iran, Russia, and the Middle East. Analysts have increasingly pointed to Beijing’s vulnerability around maritime chokepoints like Hormuz and the Strait of Malacca.

If global shipping lanes remain unstable, China faces higher transport costs, tighter energy supplies, and increased strategic vulnerability.

Meanwhile, the United States is in a far stronger position than it was during past oil shocks.

America remains one of the world’s largest oil producers thanks to shale production in places like Texas and North Dakota. If Middle Eastern instability persists and OPEC fractures further, U.S. producers could gain pricing power, export leverage, and geopolitical influence.

In the short term, oil volatility could intensify. Brent crude has already surged above $110 per barrel amid Hormuz disruptions.

But strategically, Washington appears to be positioning for something larger: a world where American energy, American shipping routes, and American-aligned producers matter more than centralized OPEC control.

If President Trump’s “global energy reset” keeps accelerating, investors should stop thinking only about oil prices and start thinking about who controls secure supply, export infrastructure, and politically stable production.

For example …

  • • Diamondback Energy (FANG)
    One of the purest plays on U.S. shale strength. If Middle Eastern instability keeps global supply tight, low-cost Permian producers like Diamondback could benefit from stronger realized pricing and rising export demand.
  • • Exxon Mobil (XOM)
    Exxon has massive upstream exposure, Gulf Coast refining capacity, and LNG infrastructure. It is also positioned to benefit if the U.S. increasingly becomes the “safe supplier” for allies trying to reduce exposure to unstable shipping lanes.
  • • Chevron (CVX)
    Chevron’s Venezuela exposure could become extremely important if Trump continues selectively reopening Venezuelan crude flows under U.S.-friendly arrangements. That would give U.S. majors leverage over barrels China once had easier access to.
  • • Occidental Petroleum (OXY)
    A Buffett-backed domestic oil name heavily tied to Permian production. If oil volatility stays elevated above historical averages, highly leveraged domestic producers could see major cash flow expansion.
  • • Kinder Morgan (KMI)
    Pipelines matter in an energy realignment. Moving oil and gas safely across North America becomes more valuable when global maritime chokepoints become less reliable.
  • • Cheniere Energy (LNG)
    One of the biggest potential winners if Europe and Asian allies continue diversifying away from unstable Middle Eastern supply and Russian energy dependence. U.S. LNG exports become strategically critical in that scenario.

Meanwhile, China could face the opposite setup.

Beijing still depends heavily on imported crude flowing through vulnerable maritime routes like the Strait of Hormuz and Strait of Malacca.

If those routes remain unstable, China absorbs higher shipping costs, insurance costs, and supply risk while the U.S. increasingly benefits from domestic production and export capacity.

This is starting to look less like a temporary oil spike and more like a long-term geopolitical restructuring of global energy power.

Most investors have heard the pitch for small modular reactors by now…

Build nuclear smaller. Build it faster. Deploy it closer to demand. Reduce cost overruns. Expand clean, reliable baseload power.

That’s a compelling story.

But there’s an even smaller, quieter, and potentially more disruptive story developing one layer below it…

I’m talking about micro modular reactors, or MMRs.

And if SMRs are meant to reshape the grid, MMRs could reshape the edge of the grid.

They’re designed for places where a full-size reactor is too big, diesel is too expensive, the power lines don’t reach, or reliability matters so much that you simply can’t afford to lose electricity for even a few minutes.

The U.S. Department of Energy describes them as compact, transportable systems that are generally designed to produce about 1 to 20 megawatts of thermal energy for electricity, heat, desalination, hydrogen, and other uses.

And that might not sound like much compared with traditional nuclear plants. But that’s the wrong way to think about it…

The right way to think about MMRs is this: they aren’t trying to replace every power plant in America.

They’re trying to serve the markets that big power plants and fragile grids don’t serve well.

And that’s where things start to get interesting.

The Nuclear Story Is Getting Smaller

For years, the nuclear conversation has revolved around scale…

Bigger plants. Bigger budgets. Bigger delays. Bigger political fights.

But advanced nuclear is flipping that old, tired logic on its head.

SMRs already challenged the assumption that nuclear has to mean one giant facility producing hundreds of megawatts.

But MMRs take that concept even further…

Description: An image of a Morpheus micro modular reactor. Source: Nuclea Energy Inc.

These are very small reactors, often designed to be factory-built, transported in modules, installed more quickly, and operated in places that would never make sense for conventional nuclear.

And the DOE says microreactors are attractive precisely because their small size can enable transportability and use in remote locations, military installations, and other hard-to-power settings.

That opens up a whole new category of demand…

Think isolated mining projects. Arctic communities. Oil and gas operations. Ports. Military bases. Disaster-response hubs. Remote industrial campuses.

Even certain data-intensive operations in places where fuel logistics and grid reliability are major problems.

In many of those markets, the alternative isn’t cheap natural gas or a massive solar farm with battery storage.

It’s often diesel. And diesel is ugly. It’s costly, dirty, logistically painful, and vulnerable to supply disruption.

That’s why MMRs matter…

They don’t need to beat every power source everywhere.

They just need to beat diesel, shipped fuel, or unreliable off-grid systems in enough niche markets to create a real commercial beachhead.

And once that beachhead is established, the market can grow from there.

Why MMRs Could Catch Investors Off Guard

This is the kind of trend the market often misses at first.

Investors love grand themes…

“The grid of the future.” “AI-powered electricity demand.” “The nuclear renaissance.”

Those narratives are easy to understand. They’re broad. They’re exciting. And they make for good headlines.

MMRs are a little different. They’re not as flashy because they sound so small.

But small can be a huge advantage…

A microreactor that fits into a transportable footprint and provides steady power and heat for years can be transformational in places where energy is a bottleneck.

BWXT’s Project Pele, for example, is a transportable microreactor sponsored by the U.S. Department of Defense and designed to generate at least 1.5 megawatts of always-on electricity while fitting into standard shipping-container logistics.

That tells you something important.

This isn’t just a science-fair concept. Serious institutions with serious energy-security needs are spending real money to move this technology forward.

The Pentagon is interested because energy resilience is national security.

The DOE is interested because microreactors could expand the commercial nuclear toolkit.

In fact, Idaho National Laboratory’s DOME test bed, which opened in April 2026, is specifically meant to accelerate real-world microreactor experiments.

Once you have government-backed testing, regulatory engagement, and early industrial use cases lining up, you no longer have just a concept. You have an emerging market.

And emerging markets are where the biggest gains usually start.

Where The Real Opportunity Could Be

The beauty of MMRs is that they don’t need universal adoption to become a major trend.

They just need to dominate specific, underserved energy niches.

Remote mining is a perfect example…

Mining projects often sit on top of strategic resources but far away from reliable power infrastructure.

If a company can bring in transportable nuclear power that runs for years and reduces dependence on diesel, the economics of certain projects could improve dramatically.

That matters in a world increasingly obsessed with domestic supply chains for copper, nickel, uranium, rare earths, and other strategic materials.

Military applications are another obvious market…

The U.S. government has made it clear that resilient, always-on power for installations and remote operations is a priority.

That’s why Project Pele exists, and it’s one reason microreactors may move faster than many investors expect.

Then there’s industrial heat…

A lot of investors still think about nuclear only as electricity. But microreactors can also provide high-temperature heat for industrial processes, which opens another door entirely.

DOE notes that microreactor output can be used directly as heat or converted into electricity, broadening the addressable market beyond just power sales.

That flexibility matters…

It means MMRs could eventually become a solution not just for electricity shortages, but for energy resilience, fuel substitution, industrial efficiency, and strategic infrastructure buildouts.

And that’s a much bigger story than most people realize.

The Companies Quietly Pushing This Forward

This is still a small and relatively unknown corner of the energy market, which means pure-play options are limited and risk is high.

But that’s also what makes it interesting.

Westinghouse is developing the eVinci microreactor for decentralized and remote applications.

And its owners include Cameco and Brookfield through their Westinghouse stake.

Westinghouse also became the first microreactor developer to secure an approved Preliminary Safety Design Report for DOME in 2025, a meaningful milestone for future testing and commercialization.

BWXT is a name we’ve already mentioned that’s worth watching…

It’s already deeply embedded in nuclear manufacturing and defense work, and it has exposure to both Project Pele and its own BANR microreactor platform.

The company says BANR is a factory-fabricated, transportable high-temperature gas reactor for remote power and industrial heat production.

And NANO Nuclear is one of the more direct public-market names in this space.

The company trades on Nasdaq under the ticker NNE and says it is focused on portable and stationary microreactor technologies.

It also acquired major assets tied to the bankrupt Ultra Safe Nuclear effort and later finalized the acquisition of Global First Power, which had been linked to the Chalk River MMR project in Canada.

That last part is worth pausing on…

Not every project in this space will succeed cleanly.

The Chalk River MMR project was paused after the original USNC effort ran into bankruptcy, and Canada’s nuclear regulator still lists the Global First Power project as paused.

That’s the risk side of the story.

This is early-stage technology. Licensing takes time. Fuel supply matters. Execution will separate the winners from the wannabes.

But early-stage messiness is not a reason to ignore a market. In many cases, it’s the price of admission.

Why This Could Become a Major Energy Trend

The energy world is changing in a way that favors technologies like MMRs.

Power demand is getting more fragmented. More strategic. More local. More resilience-focused.

It’s no longer just about feeding giant cities from giant power plants.

It’s about securing remote assets, supporting industrial clusters, hardening military infrastructure, and keeping critical operations online no matter what the grid is doing.

That’s exactly the kind of environment where micro modular reactors can thrive.

SMRs may still get the headlines… They’re easier to plug into the broader grid narrative.

But MMRs may wind up being the stealthier opportunity because they target the edge cases where the value of dependable energy is highest and the competition is weakest.

That’s often where the market’s next big winners are born.

The crowd tends to arrive after a theme becomes obvious. But smart investors start paying attention when the market still feels obscure, complicated, and just a little too early.

That’s where micro modular reactors are today…

Not mainstream. Not fully commercial. Not risk-free.

But very real. Advancing. Backed by serious institutions. And aimed directly at a set of energy problems that are only becoming more important.

So, if you want to get ahead of one of the next major trends in advanced nuclear, this is where you should be looking now.

Learn more about the companies building the hardware, supplying the fuel, solving the logistics, and pushing these reactors toward real deployment.

Because by the time this market feels crowded and obvious, the easy money may already be gone.

The NASA Artemis program just pulled off something we haven’t seen in over 50 years—a crewed mission around the Moon and safely back to Earth.

Artemis II wrapped a 10-day, nearly 700,000-mile journey, pushing humans farther into space than any mission since Apollo and proving the entire Orion system under real conditions.

I watched live as this literal moonshot hit Earth’s atmosphere at nearly 25,000 mph, endured extreme heat, and delivered a clean, textbook splashdown in the Pacific.

And it’s not just NASA stacking up the wins.

SpaceX recently completed a full-duration burn with its Starship system, demonstrating improving reliability at super-heavy scale and moving closer to consistent, repeatable launches.

With its IPO on the horizon, the company is positioning aggressively to be the industry’s 800-pound gorilla

There’s a broad shift happening in the space industry right now, and with government funding, private capital, and engineering progress aligning to expand launch capacity, orbital logistics, and future lunar infrastructure …

… it’s hard to be anything but bullish on where this industry is headed.

The question for investors is, what’s the best way to play the trend?

Well, of course, there’s the SpaceX IPO, which is projected to be the biggest IPO in history.

But for investors who want to lock in upside potential now, a little-known company called Starfighters Space (FJET) is a compelling example with a chart that indicates a potential breakout looming.

The company, which owns and operates a fleet of F104 “Starfighter” jets, primarily engages in hypersonics testing and small satellite launches.

Starfighters recently completed wind-tunnel separation of STARLAUNCH-1, testing across both subsonic and supersonic regimes, with clean separation and data aligning closely with internal aerodynamic models.

This marks a critical step toward making air-launch a repeatable, scalable system. From there, the model expands.

This company operates with multiple revenue paths already in motion — flight services, testing and evaluation, and pilot training — each tied to the same core fleet and operational infrastructure.

As development advances, that base supports future expansion into suborbital launches and short-duration microgravity missions, opening the door to higher-value contracts.

The infrastructure to support that growth already exists.

At Midland International Air & Space Port, an FAA-licensed spaceport, Starfighters continues to scale operations under a long-term agreement backed by Texas economic incentives tied to job creation and capital investment.

The fleet remains active, with plans to expand aircraft and engine capacity as demand builds.

On the financial side, the company has already taken a meaningful step forward.

Following its December 2025 listing on the NYSE American, Starfighters raised over $20 million and streamlined its capital structure.

Debt discount amortization has declined as reliance on complex convertible instruments eased. Derivative-driven volatility has come down.

Convertible debt has largely transitioned into equity post-listing, leaving a cleaner, more stable balance sheet.

Meanwhile, the stock itself has only just started to reflect that shift.

Shares are trading just above the 50-day moving average, with a bullish MACD crossover—the first since the mid-February run.

Price action has been forming a rounded base, with a loose inverse head-and-shoulders structure taking shape.

A confirmed close above the downtrend line from the past month would signal a potential breakout.

Put it all together, and this looks like a company moving through an early inflection point — operationally, financially, and technically.

For investors watching the space economy accelerate, this offers exposure to a real operator building toward its next major milestone while the broader industry continues to gain momentum.

Tim Collins

Senior Editor, Streetlight Confidential

Disclosure: The author is a shareholder and holds a long position in the company mentioned. This communication is for informational purposes only and does not constitute an offer to sell or a solicitation to buy any securities. Readers should conduct their own due diligence and consult with a licensed financial advisor before making any investment decisions.Tim Collins brings decades of Wall Street experience to Streetlight Confidential subscribers. As a hedge fund manager and investment analyst, he earned a reputation as “The Expert’s Expert” for his ability to break down complex opportunities into actionable insights. He has ghostwritten for industry figures like Jim Cramer and James Altucher, contributed to outlets such as TheStreet and RealMoney, and appeared on Mad Money. Today, he applies a disciplined mix of technical, fundamental, and risk analysis to uncover overlooked investment opportunities for readers.

The future of energy probably won’t be won by a single fuel, a single technology, or a single giant utility. 

It will be shaped by whichever solutions can deliver dependable electricity at scale, under pressure, in a world that suddenly needs a lot more power than most people expected. 

And that’s a big reason nuclear energy is finding its way back into the conversation… 

Global electricity demand rose 4.3% in 2024, according to the International Energy Agency…

Which sounds small until you realize it was equivalent to nearly 30% of all the energy the US generated that year

Then you’ve got the U.S. Department of Energy pointing to data centers as a major driver of future consumption, with estimates that they could account for up to 9% of U.S. electricity generation by 2030. 

That kind of demand growth changes the way investors ought to think about power generation. It’s no longer enough to ask what is cheap, fashionable, or politically popular. 

The real question is what can reliably keep the lights on while feeding AI infrastructure, industrial facilities, and increasingly electrified economies. 

Nuclear already supplies a meaningful share of U.S. electricity, and global policy ambition around nuclear buildouts has been rising sharply. 

World Nuclear Association said in January that government ambitions for nuclear deployment now exceed the tripling goal for 2050.

And the IAEA continues to frame small modular reactors as a flexible option for a wider range of users and applications. 

Why Small Reactors Could Become a Very Big Deal

What makes this next chapter especially interesting is that it may not be driven only by giant, traditional nuclear plants. 

Small modular reactors, or SMRs, are designed to be smaller, more flexible, and potentially easier to deploy than conventional reactors. 

The IAEA describes SMRs as reactors that can be deployed as single or multi-module plants and paired with other energy sources. 

And World Nuclear’s SMR tracker shows just how broad and active the development pipeline has become around the world. 

World Nuclear Association’s SMR Global Project Tracker map shows how widespread the global race to develop small modular reactors has become. Source: World Nuclear Association 

That matters because the old knock on nuclear was always the same: too expensive, too slow, too cumbersome, too hard to site, and too difficult to finance. 

And while SMRs don’t eliminate those challenges, they do offer a different path… 

Factory-built components, modular deployment, smaller footprints, and the ability to serve remote sites, industrial campuses, military installations, or grid-constrained regions all make the concept more attractive than the old all-or-nothing nuclear model. 

And the DOE’s Reactor Pilot Program is built around that idea, aiming to fast-track advanced reactor demonstrations and help push multiple concepts toward criticality. 

As The Grid Gets More Stressed, Nuclear Starts Looking More Practical

That’s why nuclear suddenly feels less like a legacy technology and more like a practical answer to a modern problem. 

Wind and solar will continue to play important roles, but they are not always available when power demand peaks. 

Natural gas is useful, but fuel markets and emissions concerns can complicate the picture. 

But nuclear’s appeal is that it offers firm, dispatchable, low-carbon power in a world that increasingly values reliability as much as ideology. 

DOE has also stepped up its support for American-made SMRs, including an $800 million award announced in late 2025 to TVA and Holtec to advance deployment. 

For investors, though, the real opportunity may not be in the giant incumbent names everybody already knows. 

Instead, it may be in the smaller public companies trying to carve out a niche in reactor design, microreactors, advanced fuel, and domestic nuclear supply. 

These aren’t risk-free stories. In fact, they’re exactly the kind of stories that can get messy, volatile, and speculative. 

But that’s also where the asymmetry can show up when a major industry is still in its early innings.

NANO Nuclear Is Trying to Turn Microreactors Into A Public-Market Story

One of the more intriguing names in the group is NANO Nuclear Energy. 

It’s a small public company built around advanced microreactor development, and it has been steadily trying to position itself as one of the purest public-market plays on compact nuclear systems. 

The company says its lead technology is the KRONOS MMR, a stationary high-temperature gas-cooled microreactor that is already in construction permit pre-application with the NRC, alongside other designs including ZEUS and LOKI. 

Early in April 2026, NANO said a construction permit application was submitted by the University of Illinois Urbana-Champaign for the KRONOS deployment partnership, giving the company a real regulatory milestone instead of just a PowerPoint dream. 

That doesn’t mean commercial success is guaranteed. 

But It does mean NANO is moving through the kinds of steps that separate serious developers from the crowd of companies simply hoping to catch a hot theme. 

And for speculative investors, that’s important. 

You don’t need a company like this to have all the answers yet. You just need to see signs that it is advancing from concept toward legitimacy. NANO seems to be doing that.

Eagle Nuclear Energy Brings Fuel Security Into the Same Bet

Eagle Nuclear Energy adds a different twist to the story, and that’s what makes it compelling…

Instead of offering only a reactor narrative, Eagle is pitching a more vertically integrated nuclear future. 

The company says it is pairing its SMR technology ambitions with the Aurora uranium project, which it describes as the nation’s largest conventional uranium deposit. 

In early April 2026, Eagle announced plans for a 27,000-foot drill program to move Aurora toward a pre-feasibility study, calling it one of the largest undeveloped uranium deposits in the United States. 

Eagle also only recently entered the public markets, beginning Nasdaq trading under the ticker NUCL in February 2026. 

That combination makes Eagle more interesting than a simple uranium exploration story… 

If advanced nuclear really is going to expand, the market will not just need reactors. It will need fuel, domestic supply chains, and credible North American resource leverage. 

Eagle is trying to sit in both worlds at once. That’s ambitious, and ambition in small-cap land always comes with real risk. 

But if the thesis works, it could also give investors exposure to both sides of the nuclear buildout: the fuel side and the technology side.

BWX Technologies Offers A More Grounded Way to Play the Same Trend

BWX Technologies is not as tiny or as speculative as NANO or Eagle, but it still belongs in this conversation because it gives investors a more established public foothold in advanced nuclear development. 

BWXT is deeply involved in Project Pele, the U.S. Department of Defense effort to develop a transportable microreactor. 

And the company says the Pele prototype is being designed and manufactured at its Innovation Campus in Lynchburg, and in December it announced delivery of the full core of TRISO fuel for the microreactor. 

Why does that matter? Because markets often get carried away with the pure-concept names while underestimating the companies that actually know how to build hard things. 

Project Pele is not a vague white paper. It is a real microreactor effort with government backing, tangible engineering work, and a use case centered on resilient energy supply. 

So, BWXT may not have the same lottery-ticket feel as the smaller names, but sometimes the companies that quietly execute wind up being the most durable winners.

Lightbridge Could Win Even If Someone Else Builds the Best Reactor

Then there’s Lightbridge, which is not really a reactor company at all. It is a fuel technology company, and that may be precisely why it deserves attention. 

Lightbridge says it is developing proprietary next-generation nuclear fuel for existing light-water reactors and future SMRs, with the goal of improving safety, economics, and proliferation resistance. 

The company has continued presenting technical research in 2026 and has explicitly framed its fuel as relevant to both current reactors and new SMRs. 

That creates an attractive “picks and shovels” angle…

In every major industrial buildout, some of the best opportunities come not from the final branded product, but from the enabling technology that many players may need. 

If the advanced nuclear market grows, better fuel could become one of the critical bottlenecks. That gives Lightbridge a lane, even if it never becomes a household name.

The Best Opportunities Often Show Up Before the Crowd Believes

The point here is not that every small nuclear stock is destined to soar…

Some will fail. Some will dilute shareholders. Some will take far longer than expected to hit key milestones. This is still an emerging market, and emerging markets are rarely tidy. 

But the larger trend looks increasingly real. 

Governments are pushing advanced reactor programs forward, global nuclear ambitions are climbing, and the energy needs of AI, industry, defense, and grid resilience are making dependable power more valuable by the quarter. 

That’s why this space is worth watching now, before it becomes obvious. 

Nuclear power’s role in the future energy mix is likely to be much larger than many investors currently assume, and small modular reactors could become one of the biggest reasons why. 

The lesser-known public companies chasing that future are risky, early, and imperfect. They are also exactly the kind of problem-solvers that can create outsized returns when a giant market begins to take shape.

So, start doing the homework today. Dig into the small companies trying to move advanced nuclear from idea to infrastructure. 

Learn more about the firms building microreactors, strengthening domestic uranium supply, and developing the fuels and systems that could make the whole market work. 

The next great energy story may not belong only to the giants. It may belong to the smaller public companies bold enough to build what the future suddenly needs.

For a long time, the nuclear investment story felt too simple and too hard at the same time.

Simple, because the basic pitch never changed. The world needs more reliable electricity, nuclear provides dense around the clock power, and uranium is the fuel that makes it all go.

But also hard, because the traditional nuclear industry built a reputation for giant projects, giant budgets, giant delays, and political battles that seemed to drag on forever.

That’s why the next chapter in nuclear is so exciting…

The Nuclear Opportunity Is Getting Smaller and More Interesting

It’s not just about building more reactors. It’s about building different reactors.

Small modular reactors, better known as SMRs, along with other advanced reactor designs, are being developed specifically to address many of the objections that have followed nuclear power for decades.

You see, SMRs are drawing global interest because they can offer enhanced safety through inherent and passive safety features, reduce upfront capital requirements, and provide more flexible deployment options than conventional large reactors.

For investors, that changes the shape of the opportunity…

This is no longer just a bet on the old nuclear model getting a second chance.

It’s a bet on a more practical, more flexible, and potentially more scalable version of nuclear power taking shape at exactly the moment the world needs more electricity from almost every angle.

And as that thesis keeps gaining traction, the biggest winners may not just be the reactor designers.

They may also be the companies wise enough to lock down fuel before the rest of the market realizes how important that piece of the story really is.

Why The New Reactor Designs Matter More Than Most Investors Realize

Traditional nuclear plants were designed to do one thing really well: produce a lot of electricity from one very large facility. And they’ve done that for decades.

But those plants also came with huge capital requirements, complicated construction schedules, and timelines long enough to test the patience of investors, utilities, regulators, and politicians alike.

SMRs are trying to change that equation…

Instead of asking the market to fund and build one enormous reactor all at once, SMRs are designed to be smaller, more modular, and more repeatable.

Their smaller size can reduce capital outlay and financial risk, while modular construction can allow developers to add capacity in stages rather than committing to a massive one shot project.

That doesn’t just make them sound more modern. It makes them potentially more financeable.

Some newer designs still use water cooling, but in a simplified system. Others move into alternative coolants and fuel forms altogether.

The point is not simply to shrink the footprint. The point is to make reactors that are easier to site, easier to replicate, and in many cases easier to operate safely.

In fact, many advanced reactor concepts rely less on active systems and operator intervention than older technologies, with a stronger emphasis on inherent and passive safety.

That distinction matters because one of the biggest problems nuclear has faced over the years is not just technical risk. It’s perception risk.

And the more these companies can show that new designs are simpler, more forgiving, and less vulnerable to the problems people associate with legacy plants, the more investable the whole sector becomes.

How The New Generation Is Trying to Solve Nuclear’s Old Problems

Whenever new nuclear capacity comes up, the same concerns tend to follow close behind.

People worry about safety. They worry about cost overruns. They worry about the time it takes to get projects built.

And they worry about whether nuclear can realistically fit into a modern grid that’s becoming broader and more distributed.

But that’s exactly what advanced reactor developers are trying to address.

GE Vernova Hitachi’s BWRX-300, for example, is a small boiling water reactor design with passive safety features and natural circulation.

Ontario Power Generation has moved that design into a real licensing pathway, which helps make the technology feel more like an emerging commercial product than a futuristic concept.

NuScale has also made meaningful regulatory progress, with the company announcing in May 2025 that the U.S. Nuclear Regulatory Commission approved its uprated 77-megawatt electric design.

And other players are pushing beyond conventional water cooled designs…

Privately-owned, Kairos Power is developing a fluoride salt cooled reactor. And X-energy is pursuing a high temperature gas cooled design built around TRISO fuel.

These aren’t tiny tweaks to the old formula.

They’re efforts to build reactors that can better tolerate extreme conditions, simplify safety systems, and potentially fit a wider range of industrial and grid applications.

Now, none of that means the industry suddenly becomes easy.

Nuclear will still be capital intensive. Licensing will still be demanding. First of a kind projects will still carry execution risk.

But if these companies can prove their systems work at commercial scale, they may help solve some of the very issues that kept nuclear sidelined for so long.

That’s why this matters. It’s not just a technology story. It’s a de-risking story.

Why Fuel May Be the Real Edge in Advanced Nuclear

Here’s where the conversation gets even more interesting from an investing standpoint.

A reactor developer can have brilliant engineers, beautiful renderings, and a compelling pitch about the future of clean baseload power…

But if it can’t secure fuel, it doesn’t have a real business. It has a presentation.

And that’s becoming a bigger issue because several advanced reactor designs require fuel forms that are not yet available at broad commercial scale.

The U.S. Department of Energy’s HALEU Availability Program exists specifically to help jump start private investment in domestic production of high assay low enriched uranium, or HALEU, because the market is still developing.

That’s why investors should be paying close attention to who is thinking ahead on fuel supply and who is simply assuming the market will figure it out later.

Oklo is one example of a company taking the fuel issue seriously…

In March 2026, the company announced plans to pursue a joint venture with Centrus Energy focused on fuel services in Ohio, building on an existing relationship around advanced nuclear fuel and domestic supply chain development.

TerraPower has taken a similar route…

In October 2024, TerraPower announced a term sheet with ASP Isotopes tied to a HALEU enrichment facility in South Africa and a fuel supply arrangement for TerraPower’s Natrium reactor.

That relationship progressed in May 2025, when ASP Isotopes disclosed more definitive agreements intended to support TerraPower’s fuel needs.

X-energy has gone a step further by pushing into fuel capability itself…

Its TRISO-X unit received the first NRC Part 70 HALEU fuel fabrication license in February 2026, a milestone that could prove important if the market starts rewarding companies that control more of their own supply chain.

In other words, the advanced reactor race is not just about who has the sleekest design. It’s about who can actually fuel the thing.

Why Vertical Integration Could Become A Major Advantage

That brings us to Eagle Nuclear Energy Corp, which deserves a place in this discussion precisely because it isn’t approaching the opportunity as just a uranium story or just an SMR story.

It’s trying to connect the two…

Eagle owns the Aurora Uranium Project on the Oregon/Nevada border.

The company has described Aurora as the largest conventional measured and indicated uranium deposit in the United States, and in March 2026 it engaged SLR International to lead the permitting effort there.

Then, on April 1, 2026, Eagle announced plans for a 27,000 foot drill program designed to advance Aurora toward a pre-feasibility study.

That alone would make it worth watching in a market that increasingly cares about domestic uranium supply.

But Eagle also has an SMR division and has been talking openly about its VSLLIM and SLLIM reactor concepts.

In the company’s 2026 investor presentation, Eagle says those reactor technologies are in the design stage, with the VSLLIM aimed at roughly 3.3 megawatts electric and the SLLIM aimed at roughly 33 megawatts electric.

Now, to be clear, that means this is still early. Very early.

These are not commercially deployed designs. But that doesn’t make the strategy uninteresting.

In fact, it may make Eagle one of the better examples of how this industry is evolving.

Instead of pretending the reactor and fuel stories are separate, Eagle is trying to position itself from the ground to the grid.

That’s a phrase the company itself uses, and the framework is exactly the right one.

Uranium resource ownership plus reactor ambition is a more complete strategic posture than just showing up with a concept and hoping the fuel market solves itself.

That’s why Eagle belongs in this conversation. It embodies the idea that the next nuclear winners may be the ones thinking about the whole value chain, not just one piece of it.

Why The Market Opportunity Could Be Much Bigger Than It Looks

All of this is happening against a backdrop that keeps getting more favorable for advanced nuclear.

Electricity demand is rising again. Data centers are pulling more power. Industrial reshoring is adding new load.

Electrification is spreading across transportation, heating, and manufacturing. Grids need more firmness, more resilience, and more diversity.

Advanced nuclear won’t solve all of that by itself, but it may help solve a very specific and very important part of the problem: dispatchable, carbon free, scalable power that can complement a wider and more complex energy mix.

SMRs can be deployed as single or multi module plants and can be combined with other energy sources, including renewables, which makes them extremely useful in the broader, more layered grid investors should expect over time.

And that’s what makes this story bigger than a niche reactor trade…

It’s really a story about whether a new generation of nuclear technology can earn its place in the future power stack by being more flexible, more financeable, and more secure on fuel than the legacy system that came before it.

If the answer is yes, then there’s a lot of room for capital to flow into the companies building that system.

Why Investors Should Look Past the Reactor and Into the Ecosystem

The market usually falls in love with the most obvious part of a story first. In advanced nuclear, that’s the reactor design.

It’s the flashy piece. It’s the futuristic piece. It’s the part that gets headlines.

But the more durable investing edge may come from looking deeper.

Which companies are making real licensing progress…

Which ones are pursuing designs that actually address the biggest historical concerns around nuclear power…

Which ones are pairing their technical roadmap with real fuel strategy…

And which ones are building internal capabilities, partnerships, or upstream exposure that make them less dependent on a fragile future supply chain.

That’s where the serious analysis starts.

Because in this industry, a reactor without fuel is just a very expensive idea.

The Best Advanced Nuclear Stories May Be the Ones That Planned Ahead

There’s a reason this theme is getting more compelling.

The world needs more power. It needs it from more sources. It needs it reliably.

And it needs companies that are thinking several moves ahead instead of chasing the easiest headline.

That’s why advanced nuclear deserves investor attention.

Not because every reactor startup will succeed. They won’t.

Not because every SMR concept will become commercial. It won’t.

But because the companies that combine credible technology with credible fuel strategy could end up occupying one of the most important intersections in the future of energy.

So, keep reading. Keep digging. And pay especially close attention to the businesses driving this industry forward with both reactor ambition and fuel foresight.

Because the next big winners in nuclear may not just be the ones building smarter reactors.

They may be the ones smart enough to make sure those reactors never run out of fuel.

For years, a lot of investors thought about cybersecurity in pretty simple terms…

Big targets got attacked. Banks, defense contractors, federal agencies, hospitals, maybe the occasional retailer with millions of customer records.

The average person? The local business owner? The consultant with a Gmail inbox and a half-dozen cloud logins? They didn’t feel like the main event.

But that way of thinking is getting old fast…

When The Targeting Gets “Personal”

Last week’s reported breach of FBI Director Kash Patel’s personal email account is a perfect example.

According to Reuters and the Associated Press, an Iran-linked group known as the Handala Hack Team claimed responsibility for accessing Patel’s personal Gmail account and publishing old emails, photographs, and other personal documents online.

Now, the FBI already said the exposed material was historical and didn’t involve government information.

In other words, this wasn’t a compromise of the FBI’s internal systems. It was a compromise of a person.

But that’s exactly why it matters…

The story here isn’t that some explosive government secret was exposed.

The story is that high-value individuals are increasingly targets in their own right.

State-backed hackers, politically motivated operators, cybercriminals, and hybrid threat groups aren’t just storming the front gate anymore.

They’re checking side doors, windows, private accounts, old cloud storage, personal devices, and the messy overlap between work life and home life.

That should get investors thinking, because once the threat moves from institutions to people, the addressable market for cybersecurity gets a whole lot bigger.

Why The New Perimeter Is You

Here’s the thing a lot of people still don’t fully appreciate…

The old cybersecurity model was built around the office.

Secure the company network. Lock down the servers. Put controls around the data center. Train employees not to click suspicious links and call it a day.

But that world is gone.

Now we live in a world of remote work, personal devices, shared drives, cloud apps, password reuse, online banking, digital identities, home Wi-Fi, smart devices, and constant account creation.

People don’t have one digital footprint anymore. They have dozens of them, sometimes hundreds.

And every one of those accounts, apps, subscriptions, and connected devices adds another potential entry point.

For a small business, that sprawl is even worse…

Many small and midsize businesses still don’t have formal cybersecurity maturity.

NIST’s Small Business Quick-Start Guide is aimed specifically at organizations with “modest or no cybersecurity plans in place,” which tells you plenty about the state of the market right there.

NIST also frames cybersecurity as a core risk-management issue, not an optional IT upgrade.

And that’s where the opportunity lies hidden in plain sight…

If the biggest institutions in the world still struggle to stay ahead of cyber threats, imagine how exposed the average dentist office, local manufacturer, real estate firm, wealth manager, or e-commerce startup really is.

These are businesses that often run on thin budgets, fragmented software, outsourced IT, and overworked employees who are one convincing email away from big trouble.

And on the individual side, the problem is just as obvious…

The FBI’s latest Internet Crime Report says the IC3 logged 859,532 complaints in 2024, with reported losses exceeding $16 billion, up 33% from the prior year.

The top complaint categories included phishing, extortion, and personal data breaches.

That’s not some niche risk buried in a technical white paper. That’s mainstream economic damage.

As AI Lowers the Barrier the Threat Surface Gets Wider

If this story ended with “cyber threats are growing,” that would already be enough to justify a bullish view on the industry. But there’s another layer here, and it’s a big one…

Artificial intelligence is making cyber offense more scalable.

Microsoft said in its 2025 Digital Defense Report that nation-state actors rapidly adopted AI to make operations more advanced, targeted, and scalable.

Google’s Threat Intelligence team reported in early 2026 that threat actors were increasingly integrating AI to accelerate reconnaissance, social engineering, and malware development.

That doesn’t mean every hacker is now some sci-fi supervillain. But it does mean the tools are getting better, faster, cheaper, and easier to use.

And that matters because one of the historic limits on cybercrime was labor…

Bad actors still needed time, skill, and coordination.

AI helps them write better phishing messages, research targets faster, generate believable fake content, automate portions of code development, and refine social engineering campaigns at scale.

And even modest gains in attacker productivity can create a huge headache for defenders when multiplied across millions of targets.

So now combine three things: more digital lives, more digital businesses, and more efficient attackers.

That is not a recipe for shrinking cybersecurity demand. It’s a recipe for decades of expansion.

What Starts with High Value Targets Rarely Ends There

A lot of major trends begin at the top before they flow downward…

Luxury goods. Financial products. New software tools.

Security is no different.

Today, a breach involving someone like the FBI director grabs headlines because of the symbolism.

It shows that even politically significant, security-conscious figures can still be hit through personal channels.

But markets shouldn’t read that as a one-off. They should read it as a signal…

When attackers discover that personal accounts, consumer-grade tools, and weakly secured side channels offer access, embarrassment value, leverage, or disruption potential, they don’t keep that lesson in a vault.

They apply it more broadly.

That means executives, public officials, defense personnel, medical professionals, attorneys, investors, journalists, influencers, and small business owners all become more attractive targets.

Not because each person holds classified secrets, but because personal compromise is often useful enough…

Maybe it produces extortion material. Maybe it yields financial information.

Maybe it provides credential reuse into a work account.

Or maybe it just creates enough chaos to make the attack worth it.

Why Cybersecurity Still Looks Like a Growth Industry

And here’s where the investment case gets really interesting: the public is slowly waking up to this reality.

For years, cybersecurity spending could be sold as a corporate necessity. Going forward, it’s also likely to be sold as a personal necessity.

Identity protection, password security, dark web monitoring, endpoint protection, secure communications, managed detection, zero-trust access, cloud security, and AI-driven threat intelligence are no longer products meant only for Fortune 500 companies.

They are increasingly pieces of a much wider defense stack for businesses and individuals alike.

This is why I continue to see cybersecurity as more than just another tech subsector. It’s becoming foundational infrastructure.

National defense needs it. Corporate America needs it. Small businesses need it. Families need it.

And as awareness rises, the market is likely to keep broadening from elite enterprise budgets into mass-market services and mid-market protection layers.

That’s a powerful setup for investors because cybersecurity isn’t being pushed by one flashy theme. It’s being pushed by multiple forces at once…

Digital dependence keeps growing. Threats keep evolving. Regulators keep paying attention.

Criminal losses keep rising as state-backed actors keep testing new pressure points.

And now AI is helping both defenders and attackers move faster, which only raises the urgency around the tools that can keep up.

In other words, this isn’t a fad market. It’s a necessity market.

And necessity markets can get very large.

The companies that help secure identities, devices, email, cloud workloads, networks, endpoints, payments, and personal digital lives are playing into a trend that still looks underappreciated by the broader public.

Most people still think cybersecurity is something they’ll deal with after something bad happens. And most small businesses still act like they’re too small to matter.

That complacency is exactly what expands the runway for the industry.

Before The Crowd Figures It Out

The Patel email breach may not have exposed government secrets, but it exposed something else…

The myth that cybersecurity is mostly about protecting giant institutions from giant attacks.

It’s about protecting people now too. Important people, ordinary people, business owners, employees, families, and anyone else living an increasingly digital life.

That’s why this industry still has lots of room to run.

The threats are getting smarter. The attack surface is getting wider. The public is getting more aware. And the spending response, in my view, is still in the early innings.

That should matter to investors…

Because by the time the crowd fully realizes cybersecurity isn’t optional anymore, a lot of the best opportunities may already be well on their way.

So, learn more about the threats and the growing market defending against them.

Study the companies building the tools that protect governments, corporations, small businesses, and individuals in this new threat environment.

And if you believe the digital world is only getting bigger, more connected, and more vulnerable, then don’t wait around for the crowd to bless the trade.

Get invested today, before they figure it out.